Prolactin response to antipsychotics: An inpatient study.
Adult
Antipsychotic Agents
/ pharmacology
Benzodiazepines
/ adverse effects
Bipolar Disorder
/ complications
Female
Humans
Hyperprolactinemia
/ diagnosis
Inpatients
Male
Middle Aged
Olanzapine
/ adverse effects
Prolactin
/ blood
Psychotic Disorders
/ complications
Risperidone
/ adverse effects
Schizophrenia
/ complications
Sex Factors
Time Factors
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
08
2019
accepted:
20
01
2020
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
20
5
2020
Statut:
epublish
Résumé
Antipsychotic medication, stress, gender, and age are factors that influence prolactin levels in patients with psychosis. The aim of the study was to investigate the level of prolactin response to antipsychotic treatment in acute patients, taking into account the total duration of psychosis. The study was conducted on 170 acute patients with schizophrenia spectrum disorders and bipolar disorder. Subjects were divided into three subgroups according to the duration of the psychosis (less than 5 years, between 5 and 10 years and more than 10 years of disorder duration). The initial prolactin response under antipsychotic treatment was measured, while the severity of the psychiatric symptoms was assessed with the BPRS (Brief Psychiatric Rating Scale). Hyperprolactinemia was found in 120 (70.6%) patients, amongst which 80 (66.7%) were females and 40 (33.3%) were males. The average increase in prolactinemia was 2.46 times the maximum value in women, and 1.59 times in men. Gender (β = 0.27, p<0.0001), type of antipsychotic medication according to potency of inducing hyperprolactinemia (β = -0.23, p<0.003), and the duration of psychosis over 10 years (β = -0.15, p = 0.04) significantly predicted prolactin levels, when age, diagnosis, antipsychotic category (conventional/atypical/combinations of antipsychotics), and BPRS total scores were controlled for. Prolactin levels in patients treated with antipsychotic medication appeared to depend on patients' gender, on the type of antipsychotic medication according to potency of inducing hyperprolactinemia, and on the duration of the psychosis. An increase in prolactin levels was associated with female gender, while the use of prolactin sparing antipsychotics and a duration of psychosis over 10 years were associated with lower prolactin levels.
Sections du résumé
BACKGROUND
Antipsychotic medication, stress, gender, and age are factors that influence prolactin levels in patients with psychosis. The aim of the study was to investigate the level of prolactin response to antipsychotic treatment in acute patients, taking into account the total duration of psychosis.
METHODS AND FINDINGS
The study was conducted on 170 acute patients with schizophrenia spectrum disorders and bipolar disorder. Subjects were divided into three subgroups according to the duration of the psychosis (less than 5 years, between 5 and 10 years and more than 10 years of disorder duration). The initial prolactin response under antipsychotic treatment was measured, while the severity of the psychiatric symptoms was assessed with the BPRS (Brief Psychiatric Rating Scale). Hyperprolactinemia was found in 120 (70.6%) patients, amongst which 80 (66.7%) were females and 40 (33.3%) were males. The average increase in prolactinemia was 2.46 times the maximum value in women, and 1.59 times in men. Gender (β = 0.27, p<0.0001), type of antipsychotic medication according to potency of inducing hyperprolactinemia (β = -0.23, p<0.003), and the duration of psychosis over 10 years (β = -0.15, p = 0.04) significantly predicted prolactin levels, when age, diagnosis, antipsychotic category (conventional/atypical/combinations of antipsychotics), and BPRS total scores were controlled for.
CONCLUSIONS AND RELEVANCE
Prolactin levels in patients treated with antipsychotic medication appeared to depend on patients' gender, on the type of antipsychotic medication according to potency of inducing hyperprolactinemia, and on the duration of the psychosis. An increase in prolactin levels was associated with female gender, while the use of prolactin sparing antipsychotics and a duration of psychosis over 10 years were associated with lower prolactin levels.
Identifiants
pubmed: 32017792
doi: 10.1371/journal.pone.0228648
pii: PONE-D-19-23679
pmc: PMC6999917
doi:
Substances chimiques
Antipsychotic Agents
0
Benzodiazepines
12794-10-4
Prolactin
9002-62-4
Risperidone
L6UH7ZF8HC
Olanzapine
N7U69T4SZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0228648Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Rev Recent Clin Trials. 2011 Jan;6(1):52-63
pubmed: 20868350
Psychopharmacology (Berl). 2004 Sep;175(3):367-73
pubmed: 14997280
Mayo Clin Proc. 2005 Aug;80(8):1050-7
pubmed: 16092584
Biol Psychiatry. 1994 Feb 1;35(3):151-63
pubmed: 7909693
Arch Gen Psychiatry. 1974 Oct;31(4):564-9
pubmed: 4422004
Psychoneuroendocrinology. 2003 Jan;28 Suppl 1:53-67
pubmed: 12504072
N Y State J Med. 1989 Apr;89(4):205-8
pubmed: 2733871
Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73
pubmed: 16886971
Br J Psychiatry. 2003 Mar;182:199-204
pubmed: 12611781
J Clin Psychiatry. 2000 Dec;61(12):964-72; quiz 973
pubmed: 11206608
Caspian J Intern Med. 2011 Spring;2(2):229-33
pubmed: 24024022
J Clin Psychiatry. 1987 Apr;48(4):151-4
pubmed: 2881923
Arch Gen Psychiatry. 1976 Mar;33(3):279-86
pubmed: 1259521
Indian J Psychiatry. 2013 Apr;55(2):207-8
pubmed: 23825865
Ther Clin Risk Manag. 2007 Oct;3(5):929-51
pubmed: 18473017
J Clin Psychiatry. 2004 Nov;65(11):1491-8
pubmed: 15554761
J Psychiatr Pract. 2003 Sep;9(5):344-53
pubmed: 15985953
PLoS One. 2013 Dec 02;8(12):e82749
pubmed: 24312671
Neuropsychopharmacology. 1996 Mar;14(3 Suppl):13S-21S
pubmed: 8866739
Psychiatry Res. 2004 Jul 15;127(3):227-35
pubmed: 15296822
Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:69-82
pubmed: 12650682
Psychiatry Res. 2002 Apr 15;109(3):297-302
pubmed: 11959366
Hum Psychopharmacol. 2010 Jun-Jul;25(4):281-97
pubmed: 20521318
Eur J Endocrinol. 2004 Jul;151(1):61-5
pubmed: 15248823
Neuroendocrinology. 2019;109(1):7-19
pubmed: 30889571
Clin Endocrinol (Oxf). 2003 Feb;58(2):185-91
pubmed: 12580934
Arch Gen Psychiatry. 1978 Jan;35(1):108-16
pubmed: 23087
Clin Endocrinol (Oxf). 1976 May;5(3):273-82
pubmed: 954220
Eur Neuropsychopharmacol. 2009 Sep;19(9):629-35
pubmed: 19467582
Br J Psychiatry. 2004 Jul;185:5-10
pubmed: 15231549
Psychiatry Res. 1981 Dec;5(3):317-22
pubmed: 6119716
Front Neuroendocrinol. 2017 Apr;45:25-34
pubmed: 28235557
J Clin Psychiatry. 2010 Sep;71(9):1131-7
pubmed: 20361897
Acta Psychiatr Scand. 2007 Apr;115(4):268-76
pubmed: 17355517
Am J Psychiatry. 2000 Apr;157(4):514-20
pubmed: 10739409
Arch Gen Psychiatry. 1987 Jul;44(7):604-7
pubmed: 2440412
CNS Drugs. 2007;21(11):911-36
pubmed: 17927296
Arch Gen Psychiatry. 1978 Oct;35(10):1222-7
pubmed: 29592
Rev Psiquiatr Salud Ment. 2016 Jul-Sep;9(3):158-73
pubmed: 26927534
J Psychopharmacol. 2012 May;26(5 Suppl):42-51
pubmed: 22472310
Biol Psychiatry. 1991 May 15;29(10):953-64
pubmed: 1676605
Aust N Z J Psychiatry. 2011 Oct;45(10):830-7
pubmed: 21714721